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a b s t r a c t
Antiplatelet therapy has established clinical beneﬁt on cardiovascular outcome and has
reduced the rates of re-infarction/in stent thrombosis following percutaneous coronary
intervention in acute coronary syndromes. Major bleeding episodes can occur with anti-
platelet therapy and intracranial hemorrhage (ICH) is one of the most feared complications
resulting in signiﬁcant morbidity and mortality. Identiﬁcation of high risk groups and
judicious use of antiplatelet therapy reduces the bleeding risk. Ticagrelor is a newer
P2Y12 receptor antagonist with established clinical beneﬁt. However, risks of having an
ICH with these newer molecules cannot be ignored. Here, we report a case of spontaneous
acute subdural hematoma developing in a patient on antiplatelet therapy with aspirin and
ticagrelor. Early recognition, discontinuation of the medication and appropriate manage-
ment resulted in resolution of hematoma and good clinical outcome. Authors have reviewed
the antithrombotic drugs and their tendencies in causing intracranial bleeds from a neu-
rophysicians perspective.
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In the recent times, early intervention strategies and advances
in antiplatelet therapy have reduced the risk of recurrent
coronary events and mortality in patients with acute coronary
syndromes (ACS). Antiplatelet therapy has been proven of
major clinical beneﬁt in cardiovascular clinical trials and is
routinely prescribed in secondary prevention. However, major
bleeding is a life threatening complication of triple antiplatelet
therapy, and it can increase the risk of in-hospital death by 60%.1
Also, major bleeding episodes can adversely affect long-term
prognosis by increasing the 1-year mortality and re-infarction
rates by ﬁve-fold.2 Some patient subsets are at increased risk of
having a major bleed. Ticagrelor is a newer reversible P2Y12
receptor antagonist, reported to be more effective than existing
antiplatelet therapies with a similar safety proﬁle.3 However,
long-term safety data are still awaited. Here, we report a 58-
year-old male who developed spontaneous acute subdural
hematoma (SDH) on antiplatelet therapy with Aspirin and
ticagrelor following percutaneous coronary intervention (PCI)
for a cardiac event and placing a drug eluting stent.
2. Case report
This 58-year-old male without any previous history of
ischemic heart disease was admitted to the cardiology servicesFig. 1 – CT head plain axial view. (A–C) A right temporoparietal ac
sulci and (D) intact calvaria on bone windows.with history of retrosternal burning pain of 4 h duration. He
was a diabetic, and was on oral hypoglycemic agents for 16
years. He denied smoking and was normotensive.
He was hemodynamically stable with a heart rate of 92
beats per minute and blood pressure of 150/80 mmHg.
Cardiovascular examination was unremarkable. His electro-
cardiogram showed sinus rhythm without any acute ST-T
wave changes and features of left ventricular hypertrophy.
Serial cardiac biomarkers were negative, (Troponin T –
0.019 ng/ml (0 h), <0.010 ng/ml (6 h) respectively). Transtho-
racic echocardiography was normal. He was diagnosed to have
unstable angina and was started on glycoprotein IIb/IIIa
inhibitors, antiplatelets, statins, and insulin. Coronary angio-
gram done subsequently revealed single vessel coronary
artery occlusive disease. Left main coronary artery was
normal. Left anterior descending artery was a type III vessel
with 40% occlusive lesion in mid D1 segment. Left circumﬂex
artery (LCX) was non-dominant with 80% lesion after major
OM1. Right coronary artery was dominant without any
disease. Successful Percutaneous Transluminal Coronary
Angioplasty (PTCA) and stenting were done to mid LCX with
Supraﬂex® (Cobalt Chromium Sirolimus eluting Stent system)
stent of a caliber 3.0 mm  16 mm. Patient had uneventful
recovery following the procedure, and he was discharged on
day 5 with a multitude of drugs including Aspirin, Ticagrelor,
Statins, Angiotensin Converting Enzyme inhibitors, Ranola-
zine, Nikorandil, Insulin, and Proton pump inhibitors. He was
advised a periodic follow-up.ute subdural hematoma, mild mass effect with effacement of
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with progressively increasing right hemicranial headache of 10
days duration involving the right temporoparietal and frontal
region. It was of throbbing type, present throughout the day
and was associated with nausea and vomiting. He had no
diplopia, blurring of vision, seizures, loss of consciousness, or
limb weakness. He did not complain of hematemesis,
hematuria, melena or bleeding per rectum. He denied any
history of head trauma. He was evaluated by the neurology
team and admitted for further management.
Clinical examination revealed a conscious, irritable patient
with stable hemodynamic parameters. There was no papil-
loedema or cranial nerve involvement. He did not have any
lateralizing neurodeﬁcits. Routine blood investigations includ-
ing hemogram, coagulation parameters, liver function, and
renal function tests were normal. Cardiac evaluation including
electrocardiogram, transthoracic echocardiography, and car-
diac biomarker levels were normal. Noncontrast computed
tomography (CT scan) on head revealed a right temporopar-
ietal acute SDH (Fig. 1). There was no evidence of fracture or
external contusion. Rest of the brain parenchyma was normal.
This patient had a spontaneous acute right temporoparietal
SDH.
A neurosurgical consultation was sought, and the patient
was planned for conservative therapy and observation. He was
monitored for progression of intracranial hematoma. As he
was on antiplatelet therapy and developed an intracranial
bleed, a decision was made to stop ticagrelor. He continued toFig. 2 – Repeated CT after a week. CT head plain axial view. (A–
bone windows.receive aspirin and was added on clopidogrel, as cardiologists
felt that stopping all of the antiplatelet drugs could have been
too risky. He was started on analgesics, followed by short
course of steroids and head end elevation. Headache reduced
on day 4 of therapy, and he was discharged. Repeat CT brain on
day 7 revealed a resolving hematoma as shown in Fig. 2. He
remained asymptomatic at 90-day follow-up.
3. Discussion
Intracranial hemorrhage (ICH) is the most feared bleeding
complication known to occur in a patient on antiplatelet
therapy following PCI. Here, we describe a case of spontaneous
acute SDH in a patient with ischemic heart disease on
antiplatelet therapy with Aspirin and Ticagrelor following
PCI. He recovered with no residual neurological deﬁcits.
Timely withdrawal of ticagrelor resulted in resolution of
hematoma and improvement in the patient symptoms. Early
recognition of this complication with appropriate manage-
ment resulted in a good outcome in this patient.
Bleeding complications after antiplatelet therapy have
been long recognized and well-studied in large randomized
trials. They constitute a key safety end point in all clinical trials
assessing newer antiplatelet drugs in ACS.4 In clinical trials,
major bleeding is reported in 1–10% of all patients on
antiplatelet therapy, and it is a cause of signiﬁcant morbidity
and mortality.5 The factors predisposing to increased risk ofC) Resolving subdural hematoma and (D) intact calvaria on
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weight, impaired renal function, base line anemia, and
previous history of intracerebral haemorrhage.6 It is interest-
ing to note that ICH is uniformly classiﬁed as fatal/life
threatening bleeding as per PLATO,7 TIMI,8 and GUSTO9 trial
deﬁnitions, though deﬁnition of a major bleed varies from
trial-to-trial. Occurrence of ICH in turn is associated with
increased risk of mortality and residual neurological deﬁcit.
Though a ﬁve-fold increase in risk of mortality/re-infarction
rates at 1-year follow-up has been reported, causal link
between bleeding and recurrent ischemic event is not proven.2
Connolly et al.10 analyzed the risk of SDH in patients on
aspirin therapy. In 4 published trials with 6565 participants, 8
cases of SDH were reported. Also in another 5 large unpublished
series (90,689 participants), 18 cases of SDH were recognized.
The published incidence of SDH was 0.02/1000 patient years onTable 1 – Antiplatelet therapy in cardiovascular trials and risk 
Drug & dose Risk of ICH Monitori
Aspirin 81–325 mg Absolute annual risk of
0.03%19
NA 
Prasugrel 60 mg bolus, 10 mg
OD
0.4%20 NA 
Clopidogrel loading dose:
600 mg, 75 mg maintenance
0.33%21 NA 
Aspirin + Clopidogrel 75 mg
+ 75 mg with placebo and
aspirin 75 mg
Aspirin + clopidogrel 0.3%
vs. aspirin22 alone 0.3%. RR:
0.96
NA 
Aspirin + Clopidogrel
+ Tiroﬁban
RR similar to ASP
+ clopidogrel23
Platelet
/ACT/aPT
Ticagrelor 90 mg, 180 mg 0.3%13 NA 
Unfractionated heparin
5000 IU
0.7%24 aPTT 
Enoxaparin 40 mg 0.8%24 aPTT, PT
anti-Xa
activity
Abciximab 0.25 mg/kg IV
bolus, later 0.125 mg/kg/min
for 12 h
0.07%25 aPTT/AC
Warfarin 2.5–5 mg 1.8%/year (>75 years), 0.6%/
year (<75 years)26
PT/INR 
Acenocoumarol 2 mg, 3 mg,
5 mg
ICH risk 0.2% per year27 PT/INR 
Dabigatran 150 mg, 110 mg 0.31%28 NA 
Rivaroxaban 20 mg 0.5%29 NA 
Apixaban 5 mg 0.24%30 NA aspirin with pooled odds ratio of 1.6, suggesting that Aspirin was
a safe antiplatelet therapy. Wong et al.11 observed that
incidence of lobar hematoma was more (32.8%) in aspirin users
compared to control groups (10.3%), and this was statistically
signiﬁcant.
Bakheet et al.12 have reported on a meta-analysis of 11
randomized trials analyzing the incidence of SDH in patients on
dual antiplatelet therapy (with Aspirin and Clopidogrel).
Though 8 trials did not show any case of SDH, 3 trials involving
23,136 participants reported 39 cases of SDH. They concluded
that there was no increased absolute risk of SDH in-patient on
dual antiplatelet therapy. However, there was an increased risk
noted in Aspirin and Clopidogrel sub-group compared to Aspirin
alone group.
Ticagrelor is a newer reversible P2Y12 receptor antagonist
which is reported to have good cardiovascular outcome inof intracranial hemorrhage.
ng Activity reversal in surgical
emergency
Comments
DDAVP, platelets,
cryoprecipitate, EACA, fresh
frozen plasma
Increases the risk of ICH
1.65-fold. Association is not
statistically signiﬁcant
NA Increased risk of intracranial
bleed
DDAVP, platelet transfusion No effective tests to depict
the drug level during acute
bleeding
DDAVP, cryoprecipitate,
EACA, fresh frozen plasma
Dual therapy has no
statistically increased risk of
ICH
T
Compression over access site,
platelet transfusion
ISARCOOL trial did not show
any increase in ICH risk
NA Fatal ICH in ticagrelor group
was higher compared to
clopidogrel group
Protamine sulfate Safe, long term use risks
thrombocytopenia
, Protamine sulfate Caution while switching over
from enoxaparin to oral
anticoagulants
T Compression over arterial
access site, fresh platelet
transfusion
Safety proﬁle similar to
heparin
Vitamin K, FFP Commonest cause of drug
induced ICH in practice
Vitamin K, FFP Concomitant use of
antiplatelets with
anticoagulation associated
with increased risk of
bleeding
NA Safer than warfarin in ICH
risk. However, risk of major
bleed higher than warfarin
NA Safer than warfarin (0.5% vs.
0.7%, p = 0.02)
NA Safer than warfarin
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outcome trial (PLATO)7was a randomized, double-blind parallel
group, multicentric clinical study comparing efﬁcacy of Tica-
grelor and Clopidogrel in 18,624 participants with ACS. Rates of
major bleeding in both the groups were similar. ICH was seen in
27 cases (0.3%) in the Ticagrelor arm and 14 cases (0.2%) in the
Clopidogrel arm ( p = 0.08). However, fatal outcomes secondary
to bleed were more in Ticagrelor group (11 cases – 0.12%) when
compared to Clopidogrel group (1 case – 0.0%) ( p = 0.02).13
Though risks of ICH were not statistically signiﬁcant, mortality
was higher in the Ticagrelor group (relative risk – 5.47). Bleeding
events resulted in permanent discontinuation of ticagrelor
compared to clopidogrel (2.4% vs. 1%, p < 0.001). However, this
trial reported a net clinical beneﬁt (a composite end point of
cardiovascular death, myocardial infarction, stroke, and major
bleeds) that favored Ticagrelor over Clopidogrel ( p = 0.026).
However, neurophysicians are cautious in patients on these
medications as there is no reversal agent available14 to
counteract bleeding due to ticagrelor in life threatening bleeds
and monitoring their activity is an uphill task.
Antiplatelet therapy is known to improve cardiovascular
outcomes in ACS. Table 1 depicts the relative risks of having an
ICH on the commonly used antiplatelet therapies. Strategies
recommended15 to reduce bleeding complications include use
of low dose aspirin, restricting the use of theinopyridine
therapy following PCI to 2 weeks for angioplasty, for 4 weeks in
cases of bare metal stent insertion, and for 12 months if DES is
placed. Peterson et al.16 in their study noted that for every 10%
increase in adherence to guidelines, there is a possible 10%
reduction in mortality.
Unfortunately, there are no data on volume, location of
hematoma, and different ICH subtypes in patients with
antiplatelet therapy associated ICH. Volume of hematoma is
the single-most important predictor of clinical outcome in
patients with ICH.17 Furthermore, elderly people have a higher
risk of fall, with 30% of people older than 65 and 50% of people
older than 80 falling at least once a year,18 increasing the risk of
traumatic brain injury. Patients on antiplatelet therapy may
have higher risk of having a large volume ICH and thus indirectly
contributing to the poorer outcome in such scenarios.
To the treating neurophysicians, newer antiplatelet thera-
pies throw newer challenges. They are more potent, their
actions are difﬁcult to monitor and there are no reversal agents
available if needed in case of neurosurgical emergencies.
Stopping these drugs in a perioperative setting may be equally
hazardous on one hand; achieving hemostasis during emer-
gency neurosurgical intracranial interventions is more difﬁcult
on the other. Though it is advantageous to have an antiplatelet
medication, which does not require regular monitoring of its
effect, same can sum up as a disadvantage, when the patient
develops an intracranial bleed requiring neurosurgical inter-
vention and monitoring needs priority. Hence, caution needs to
be exercised in prescribing these medications to optimize the
therapeutic beneﬁts.
4. Conclusion
This case depicts a possible association of spontaneous acute
SDH and antiplatelet therapy with aspirin and ticagrelor.Though Ticagrelor is found to be superior to other ADP
antagonists in reducing cardiovascular morbidity, it has
increased risk of life threatening ICH compared to clopidogrel.
Treating cardiologist must identify patient subsets with
increased risk of bleeding while prescribing antiplatelet therapy
and design appropriate treatment strategies to improve clinical
outcome.
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